The distribution of CD45R, CD29 and CD45RO (UCHL1) antigens in mature CD4 positive T-cell leukaemias. by Worner, I, Matutes, E, Beverley, P, Catovsky, D

Fludarabine plus cyclophosphamide induces better response rates and progression-free survival across all age and risk groups in the LRF CLL4 trial (on behalf of the UKNCRI CLL Tria... by Catovsky, D, Richards, S, Dearden, C, Matutes, E, Dyer, M, Hillmen, P

The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry. by Matutes, E, Bosanquet, A, Wade, R, Richards, S, Else, M, Catovsky, D

The use of individualized tumor response testing in treatment selection: Second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry by Matutes, E, Bosanquet, A, Wade, R, Richards, S, Else, M, Catovsky, D

Prognostic significance of membrane antigens and morphology in chronic lymphocytic leukemia. by Matutes, E, Halsey, J, Morilla, R, Atkinson, S, Marco, J, Richards, S, Catovsky, D, Party, M

Response to therapy and survival in CLL is influenced by genetic markers. preliminary analysis from the LRF CLL4 trial. by Catovsky, D, Richards, S, Matutes, E, Burford, A, Brito-Babapulle, V, Dearden, C, Morris, P, Pettitt, A

Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. by Oscier, D, Wade, R, Davis, Z, Morilla, A, Best, G, Richards, S, Else, M, Matutes, E, Catovsky, D

Prognostic factors in the UK LRF CLL4 trial by Oscier, D, Richards, S, Orchard, J, Davis, Z, Morilla, A, Brito-Bapapulle, V, Matutes, E, Pettitt, A, Catovsky, D

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. by Gonzalez, D, Martinez, P, Wade, R, Hockley, S, Oscier, D, Matutes, E, Dearden, C, Richards, S, Catovsky, D, Morgan, G

Prognostic factors in the UK LRF CLL4 trial. by Oscier, D, Richards, S, Orchard, J, Davis, Z, Best, G, Morilla, A, Brito-Bapapulle, V, Matutes, E, Pettitt, A, Catovsky, D

Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing. by Bosanquet, A, Richards, S, Wade, R, Else, M, Matutes, E, Dyer, M, Rassam, S, Durant, J, Scadding, S, Raper, S, Dearden, C, Catovsky, D

Mutational Status of the TP53 Gene as a Predictor of Response and Survival in CLL Patients with and without 17p Deletion by Gonzalez, D, Martinez, P, Wade, R, Hockley, S, Brito-Babapulle, V, Oscier, D, Matutes, E, Dearden, C, Richards, S, Catovsky, D, Morgan, G

Gender as a prognostic factor in CLL. Biological pointers to the improved outcome of women. by Catovsky, D, Matutes, E, Morilla, A, Burford, A, Brito-Babapulle, V, Del-Giudice, I, Orchard, J, Oscier, D, Halsey, J, Richards, S

CHARACTERIZATION OF BLAST CELLS IN CHRONIC GRANULOCYTIC-LEUKEMIA IN TRANSFORMATION, ACUTE MYELOFIBROSIS AND UNDIFFERENTIATED LEUKEMIA .2. STUDIES WITH MONOCLONAL-ANTIBODIES AND TER... by Miguel, J, Decastro, J, Matutes, E, Rodriguez, B, Polli, N, Zola, H, Mcmichael, A, Bollum, F, Thompson, D, Goldman, J, Catovsky, D

Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. by Oscier, D, Dearden, C, Eren, E, Erem, E, Fegan, C, Follows, G, Hillmen, P, Illidge, T, Matutes, E, Milligan, D, Pettitt, A, Schuh, A, Wimperis, J

Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration. by Lin, K, Adamson, J, Johnson, G, Carter, A, Oates, M, Wade, R, Richards, S, Gonzalez, D, Matutes, E, Dearden, C, Oscier, D, Catovsky, D, Pettitt, A

Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. by Skowronska, A, Parker, A, Ahmed, G, Oldreive, C, Davis, Z, Richards, S, Dyer, M, Matutes, E, Gonzalez, D, Taylor, A, Moss, P, Thomas, P, Oscier, D, Stankovic, T

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. by Catovsky, D, Richards, S, Matutes, E, Oscier, D, Dyer, M, Bezares, R, Pettitt, A, Hamblin, T, Milligan, D, Child, J, Hamilton, MS, Dearden, C, Smith, A, Bosanquet, A, Davis, Z, Brito-Babapulle, V, Else, M, Wade, R, Hillmen, P

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the... by Pettitt, A, Jackson, R, Carruthers, S, Dodd, J, Dodd, S, Oates, M, Johnson, G, Schuh, A, Matutes, E, Dearden, C, Catovsky, D, Radford, J, Bloor, A, Follows, G, Devereux, S, Kruger, A, Blundell, J, Agrawal, S, Allsup, D, Proctor, S, Heartin, E, Oscier, D, Hamblin, T, Rawstron, A, Hillmen, P